{"count": 2, "results": [{"_id": "33744038", "pmid": 33744038, "title": "Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia.", "journal": "Nutr Metab Cardiovasc Dis", "authors": ["Climent E", "Marco-Benedí V", "Benaiges D", "Pintó X", "Suárez-Tembra M", "Plana N", "Lafuente H", "Ortega-Martínez de Victoria E", "Brea-Hernando Á", "Vila À", "Civeira F", "Pedro-Botet J"], "date": "2021-05-06T00:00:00Z", "doi": "10.1016/j.numecd.2021.01.014", "meta_date_publication": "2021 May 6", "meta_volume": "31", "meta_issue": "5", "meta_pages": "1594-1603", "score": 50274.965, "text_hl": "CONCLUSION: According to the LDL cholesterol reduction in @<m>DISEASE_Pierre_Robin_syndrome_with_fetal_chondrodysplasia</m> @DISEASE_MESH:C535776 @@@HeFH@@@ @SPECIES_9606 @@@patients@@@, the ranking for more to less potent statins was @CHEMICAL_Rosuvastatin_Calcium @CHEMICAL_MESH:D000068718 @@@rosuvastatin@@@, @CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin@@@ and @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@; however, at maximum dosage, @CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin@@@ and @CHEMICAL_Rosuvastatin_Calcium @CHEMICAL_MESH:D000068718 @@@rosuvastatin@@@ were nearly equivalent. ", "citations": {"NLM": "Climent E, Marco-Benedí V, Benaiges D, Pintó X, Suárez-Tembra M, Plana N, Lafuente H, Ortega-Martínez de Victoria E, Brea-Hernando Á, Vila À, Civeira F, Pedro-Botet J. Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia. Nutr Metab Cardiovasc Dis. 2021 May 6;31(5):1594-1603. PMID: 33744038", "BibTeX": "@article{33744038, title={Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia.}, author={Climent E and Marco-Benedí V and Benaiges D and Pintó X and Suárez-Tembra M and Plana N and Lafuente H and Ortega-Martínez de Victoria E and Brea-Hernando Á and Vila À and Civeira F and Pedro-Botet J}, journal={Nutr Metab Cardiovasc Dis}, volume={31}, number={5}, pages={1594-1603}}"}}, {"_id": "7737266", "pmid": 7737266, "title": "Heterozygous familial hypercholesterolaemia is associated with pathological exercise-induced leakage of muscle proteins, which is not aggravated by simvastatin therapy.", "journal": "Eur J Clin Invest", "authors": ["Smit JW", "Bär PR", "Geerdink RA", "Erkelens DW"], "date": "1995-02-01T00:00:00Z", "doi": "10.1111/j.1365-2362.1995.tb01530.x", "meta_date_publication": "1995 Feb", "meta_volume": "25", "meta_issue": "2", "meta_pages": "79-84", "score": 50087.64, "text_hl": "@<m>DISEASE_Pierre_Robin_syndrome_with_fetal_chondrodysplasia</m> @DISEASE_MESH:C535776 @@@Heterozygous familial hypercholesterolaemia@@@ is associated with pathological exercise-induced leakage of muscle proteins, which is not aggravated by @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ therapy.", "citations": {"NLM": "Smit JW, Bär PR, Geerdink RA, Erkelens DW. Heterozygous familial hypercholesterolaemia is associated with pathological exercise-induced leakage of muscle proteins, which is not aggravated by simvastatin therapy. Eur J Clin Invest. 1995 Feb;25(2):79-84. PMID: 7737266", "BibTeX": "@article{7737266, title={Heterozygous familial hypercholesterolaemia is associated with pathological exercise-induced leakage of muscle proteins, which is not aggravated by simvastatin therapy.}, author={Smit JW and Bär PR and Geerdink RA and Erkelens DW}, journal={Eur J Clin Invest}, volume={25}, number={2}, pages={79-84}}"}}]}